Laidlaw analyst, Francois Brisebois, reiterated his Buy rating on shares of Flexion Therapeutics (NASDAQ: FLXN) and raised his price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE